Supernus Pharmaceuticals
SUPN
274 hedge funds and large institutions have $1.73B invested in Supernus Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 103 increasing their positions, 91 reducing their positions, and 49 closing their positions.
13% more repeat investments, than reductions
Existing positions increased: 103 | Existing positions reduced: 91
0.24% more ownership
Funds ownership: 99.07% → 99.31% (+0.24%)
5% less funds holding
Funds holding: 288 → 274 (-14)
27% less first-time investments, than exits
New positions opened: 36 | Existing positions closed: 49
33% less call options, than puts
Call options by funds: $7.41M | Put options by funds: $11.1M
34% less capital invested
Capital invested by funds: $2.6B → $1.73B (-$877M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$18M |
| 2 |
SI
Scout Investments
Kansas City,
Missouri
|
+$14.1M |
| 3 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
+$11.8M |
| 4 |
WG
Winton Group
London,
United Kingdom
|
+$11.3M |
| 5 |
CIP
Champlain Investment Partners
Burlington,
Vermont
|
+$10.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$29.8M |
| 2 |
O
OppenheimerFunds
New York
|
-$16.7M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$12.4M |
| 4 |
Wells Fargo
San Francisco,
California
|
-$7.87M |
| 5 |
RIM
Ranger Investment Management
Dallas,
Texas
|
-$7.84M |
SUPN Hedge Fund Activity: Q4 2018 in Review
274 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Supernus Pharmaceuticals (SUPN) for Q4 2018, worth a combined $1.73B — down 34% from $2.6B a quarter earlier.
Sellers outnumbered buyers: 49 funds closed out of SUPN and 36 opened new positions — a net loss of 13 holders — while 91 trimmed existing stakes and 103 added.
The largest buyer was Marshall Wace, adding an estimated $18M. The largest seller was Invesco, cutting an estimated $29.8M.
- 274 institutional investors held Supernus Pharmaceuticals (SUPN) as of Q4 2018, down from 288 in Q3 2018.
- Funds reported $1.73B of Supernus Pharmaceuticals stock for Q4 2018, down 34% quarter-over-quarter.
- 36 funds opened new Supernus Pharmaceuticals positions in Q4 2018 and 49 closed out, a net change of -13 holders.
- The largest Supernus Pharmaceuticals buyer in Q4 2018 was Marshall Wace, an estimated $18M added.
- The largest Supernus Pharmaceuticals seller in Q4 2018 was Invesco, an estimated $29.8M sold.
Based on aggregated 13F filings for Q4 2018.